ReviewJournal of thrombosis and thrombolysis2014
The pharmacology of novel oral anticoagulants.
Review in Journal of thrombosis and thrombolysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism · 2024Article
- Association of ABCB1 gene polymorphisms rs1128503, rs2032582, rs4148738 with anemia in patients receiving dabigatran after total knee arthroplasty.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Article
- Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?Diagnostics (Basel, Switzerland) · 2023Review
- A Case of Necrotizing Periodontitis in a Care-Requiring Elderly Person Treated and Managed by Interprofessional Collaboration.Dentistry journal · 2022Article
- Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.British journal of clinical pharmacology · 2021Review
- Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE).Journal of thrombosis and thrombolysis · 2021Review
- Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease.Medicina (Kaunas, Lithuania) · 2021Review
- Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area.Pharmaceutics · 2021Article
- Bariatric Surgery can Lower the Efficacy of DOACs.European journal of case reports in internal medicine · 2020Article
- Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation.Journal of clinical medicine · 2019Article
- A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting.Critical care explorations · 2019Article
- Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report.Medicine · 2019Article
- Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature.World journal of clinical cases · 2019Article
- Atrial Fibrillation in Older People: Concepts and Controversies.Frontiers in medicine · 2019Review
- Article
- Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture.World journal of gastroenterology · 2018Article
- Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.Journal of the American Heart Association · 2018Review
- Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.International journal of hepatology · 2018Review
- Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.The American journal of medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke in non-valvular atrial fibrillation. These agents offer practical advantages over traditional vitamin K antagonists, however an understanding of their individual pharmacokinetic and other agent-specific differences is essential for identifying appropriate candidates for therapy, and for selecting the appropriate agent that will be effective and safe. Here, we review the pharmacokinetic process of oral medication use, summarize the newer anticoagulants, their pharmacology, individual pharmacokinetic features, and explore possible explanations for the differences in bleeding outcomes observed in the clinical trials.
Indexed as
Identifiers
23860880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.